AzTrials
AzTrials

Public Speaking AnxietyVREX2NCT07323498

Enhancing Generalization of Virtual Reality Exposure for Public Speaking Anxiety

A study testing VR Exposure, Standard Mental Rehearsal and Mental Rehearsal With Extinction Memory Updating in people with Public Speaking Anxiety and Public Speaking Fear, run by Philipps University Marburg at 1 site in Germany.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This randomized controlled trial examines whether imagery-based extinction memory updating following a standardized virtual reality (VR) exposure session improves the generalization of exposure effects to novel public speaking contexts. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Public Speaking Anxiety, Public Speaking Fear
What is being tested?
VR Exposure, Standard Mental Rehearsal and Mental Rehearsal With Extinction Memory Updating
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
1 siteGermany
Study dates
26 Nov 2025to Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • speech anxiety scale score of ≥ 18 on the Personal Report of Communication Apprehension, Public Speaking Subscale (PRCA-PS)
  • Self-report of 18 - 70 years of age

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Germany1 site, 1 recruiting
  • Department of Psychology, Philipps-University of Marburg

    Marburg, Hesse, 35037

    Christoph Benke, Ph.D., +49 6421 28-24091, christoph.benke@uni-marburg.de

    Recruiting

Other trials in Germany

About this study

Official title: Enhancing Generalization of Virtual Reality Exposure for Public Speaking Anxiety Via Imagery-Based Extinction Memory Updating: A Randomized Controlled Trial

This randomized controlled trial examines whether imagery-based extinction memory updating following a standardized virtual reality (VR) exposure session improves the generalization of exposure effects to novel public speaking contexts. Individuals with elevated public speaking anxiety will complete a single-session VR speech exposure. Participants are randomized to (a) standard mental rehearsal of the exposure experience or (b) mental rehearsal plus guided imagery that updates the extinction memory with novel, non-exposed contexts. Generalization is assessed 7-14 days later using a multi-context behavioral approach test (BAT) in vivo and in VR.

Read the detailed description

Exposure-based interventions are highly effective in the treatment of anxiety disorders; however, fear reduction achieved during exposure is often limited to the specific situations and stimuli encountered during treatment. As a result, fear may re-emerge when individuals face novel situations, a phenomenon commonly referred to as return of fear. This limited generalization is assumed to reflect the context- and stimulus-specific nature of extinction learning. While increasing variability across exposure contexts can enhance generalization, this approach typically requires longer treatment duration and increased therapeutic burden. Therefore, strategies that promote extinction generalization without increasing exposure time are of high clinical relevance.

Experimental laboratory research has demonstrated that extinction generalization can be enhanced by updating the extinction memory through mental imagery. Specifically, retrieving a recently acquired extinction memory and integrating novel, non-experienced stimuli or situations through imagination has been shown to reduce fear responses to both imagined and previously unencountered stimuli. This process is thought to increase the accessibility and robustness of inhibitory extinction memories by integrating new information into the existing memory network. The present study aims to translate this experimentally established mechanism into a clinically relevant intervention.

In this randomized controlled trial, individuals with elevated public speaking anxiety complete a standardized, single-session virtual reality (VR) speech exposure consisting of repeated short oral presentations across different VR contexts. Following exposure, participants are randomized to one of two imagery-based post-exposure procedures. In the control condition, participants engage in guided mental rehearsal of the previously experienced VR exposure situations. In the experimental condition, participants additionally update the extinction memory by vividly imagining having the same successful exposure experience in two novel public speaking situations: (1) giving a speech in front of a small real audience and (2) giving a speech in a VR environment with a substantially larger audience than experienced during exposure. These imagined situations are not directly experienced during the intervention but are intended to be integrated into the existing extinction memory through guided imagery.

Generalization of exposure effects is assessed 7-14 days after the intervention using a multi-context behavioral approach test (BAT). The BAT includes oral presentations in (a) situations that were directly experienced during VR exposure, (b) situations that were previously imagined during the extinction memory updating procedure, and (c) novel situations that were neither experienced nor imagined before. This design allows for the differentiation between responses to previously experienced, imagined, and entirely new public speaking contexts, thereby providing a stringent test of extinction generalization.

Primary outcomes include public speaking anxiety at follow-up as well as subjective fear ratings during each behavioral approach test, with a focus on differences between study groups across the different BAT contexts. Secondary outcomes include anticipatory anxiety prior to each BAT and behavioral performance indexed by speech duration. Baseline measures of anhedonia and positive emotionality are assessed to examine individual differences in treatment response.

Being tested
VR Exposure, Standard Mental Rehearsal, Mental Rehearsal With Extinction Memory Updating
Keywords
virtual reality exposure, extinction generalization, fear extinction, exposure therapy
Medical subject headings
Glossophobia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VR ExposureBehavioural

    6 VR speech exposure trials (3 min each; topic: "something you are proud of")

  • Standard Mental RehearsalBehavioural

    Post-exposure guided imagery: vivid mental rehearsal of the same exposure experience in the same VR contexts (brief, ≤30s each)

  • Mental Rehearsal With Extinction Memory UpdatingBehavioural

    Post-exposure guided imagery: vivid rehearsal of the exposure experience while updating the extinction memory with novel, non-exposed contexts (e.g., speaking to three real listeners; speaking in a new VR context with a larger audience). Brief, ≤30s each

Study groups in NCT07323498
Study groupRoleWhat they receive
VR Exposure + Standard Mental RehearsalActive comparatorSingle-session VR exposure intervention: 6 VR speech exposure trials \& Post-exposure standard mental rehearsal
Receives: Behavioral: VR Exposure; Behavioral: Standard Mental Rehearsal
VR Exposure + Mental Rehearsal With Extinction Memory UpdatingExperimentalSingle-session VR exposure intervention: 6 VR speech exposure trials \& Post-exposure mental rehearsal with updating the extinction memory with novel, non-exposed contexts
Receives: Behavioral: VR Exposure; Behavioral: Mental Rehearsal With Extinction Memory Updating

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Public Speaking Anxiety

    Assessed using the Personal Report of Communication Apprehension, Public Speaking Subscale (PRCA-PS). Scores range from 6 to 30, with higher scores associated with higher public speaking anxiety.

    Measured: From enrollment to one-week follow-up assessment

  2. Subjective Fear During Behavioral Approach Tests

    Self-reported fear during oral presentations, rated on a scale from 0 (no fear) to 100 (severe fear) during each behavioral approach test. Participants were instructed to speak for up to three minutes and could terminate the task at any time.

    BAT 1: Oral presentation in vivo in front of 3 real listeners BAT 2: Oral presentation in a simulated videoconference with a large audience (30 listeners) BAT 3: Oral presentation in virtual reality (exposure context 1; familiar) BAT 4: Oral presentation in virtual reality (exposure context 2; familiar) BAT 5: Oral presentation in virtual reality (novel context with ~50 virtual listeners) BAT 6: Oral presentation in virtual reality (novel context with ~100 virtual listeners)

    Measured: one-week follow-up assessment

Secondary outcomes (5)
  1. Social Anxiety Severity

    Severity of social anxiety symptoms assessed using the Social Phobia Inventory (SPIN). Scores range from 0-68, with higher scores indicating greater social phobia.

    Measured: From enrollment to one-week follow-up assessment

  2. Anticipatory Anxiety Before BATs

    Self-reported anticipatory anxiety assessed immediately before each behavioral approach test on a scale from 0 (no fear) to 100 (severe fear).

    Measured: One-week follow-up assessment

  3. Behavioral Performance During BATs (Duration of oral presentation during BATs)

    Duration of oral presentation during each behavioral approach test, measured in seconds. Participants were instructed to speak for up to three minutes and could terminate the task at any time.

    Measured: One-week follow-up assessment

  4. Valence of Public Speaking

    Self-report measure assessing how participants feel about having to give a speech. Valence is rated on a 7-point Likert scale ranging from extremely unpleasant to extremely pleasant (-3 = extremely unpleasant, -2 = moderately unpleasant, -1= slightly unpleasant, 0 = neutral, 1= slightly pleasant, 2= moderately pleasant, 3=extremely pleasant). Higher scores indicate more pronounced pleasantness.

    Measured: From enrollment to immediately post-treatment assessment and one-week follow-up assessment

  5. Anticipated Fear of Public Speaking

    Participants rate their anticipated fear of giving a speech using a visual analog scale ranging from 0 (no fear) to 100 (extreme fear).

    Measured: From enrollment to immediately post-intervention and 1-week follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jan 2026
  2. Study start26 Nov 2025
  3. Primary completionNov 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
48 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07323498
Sponsor's protocol ID
VREX2.0
Acronym
VREX2
Status last verified
Jan 2026
First submitted
22 Dec 2025
Last updated
9 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing VR Exposure, Standard Mental Rehearsal and Mental Rehearsal With Extinction Memory Updating in people with Public Speaking Anxiety and Public Speaking Fear, run by Philipps University Marburg at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Christoph Benke, Ph.D. (+49 6421 28-24091, christoph.benke@uni-marburg.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Public Speaking Anxiety (time frame: From enrollment to one-week follow-up assessment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in